Loading...
Acid-reducing agents — antacids, histamine-2–receptor antagonists, and proton-pump inhibitors — are commonly used in medical practice and may interact with antiretroviral medications. Investigators recently conducted a series of four clinical studies to evaluate the effects of acid-reducing agents on drug levels of boosted elvitegravir. Elvitegravir, a once-daily integrase inhibitor, is a component of the elvitegravir/cobicistat/FTC/tenofovir single-tablet regimen (Stribild).
The four studies were all manufacturer-sponsored, phase I, single-center, open-label, crossover trials, conducted in healthy adult volunteers:
Study 1 evaluated ritonavir-boosted elvitegravir, taken alone or simultaneously with an antacid.
Study 2 evaluated elvitegravir/r…